BioSpace News Archive

NLS Pharmaceutics Ltd. announced the closing of its previously announced registered direct offering with health-care focused institutional investors alongside participation from the Company’s Chairman of the Board of Directors, Ronald Hafner, for the purchase and sale of 4,200,000 of the Company’s common shares at a purchase price of $1.04 per common share.

Infinity Fuel Cell and Hydrogen, Inc., a global leader in hydrogen fuel cells and electrolyzers for aerospace applications, today announced signing a contract add-on with NASA’s Game Changing Development program and NASA’s Glenn Research Center in Cleveland, Ohio.

AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human extravascular implantable cardioverter defibrillator (EV-ICD) study during the upcoming Stanford Biodesign New Arrhythmia Technologies Retreat.

According to Report, the global topical drug delivery market size is projected to be worth around US$ 161.59 billion by 2029 and growing at a CAGR of 6.7% from 2022 to 2030.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first quarter of 2022.

Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2022 operating results on Tuesday, May 10, 2022, after market close.

Sharps Compliance Corp. announced that it has rescheduled the release of its third quarter 2022 financial results.

Rezolute, Inc. (Nasdaq: RZLT), today announced a late-breaking oral presentation of its Phase 2b RIZE Study Topline Data of RZ358 in congenital hyperinsulinism (HI) at the upcoming Pediatric Endocrine Society 2022 Annual Meeting on May 1, 2022.

Jasper Therapeutics, Inc., (NASDAQ: JSPR) today announced updated efficacy, safety and pharmacokinetic data from its ongoing multicenter Phase 1 clinical trial of JSP191, the company’s first-in-class anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

Penumbra, Inc. announced that its management team is scheduled to present at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022.